Body Composition Stack
GH secretagogues + fat oxidation for body recomposition research.
Extends the CJC/Ipamorelin base with AOD-9604 for targeted lipolysis and MOTS-c for mitochondrial biogenesis. This stack covers GH secretion, fat oxidation, and mitochondrial efficiency simultaneously.
What's in this stack
Research Protocol
- CJC-1295 + Ipamorelin: 100+100 mcg pre-sleep
- AOD-9604: 300 mcg AM fasted
- MOTS-c: 5 mg twice weekly
Ready to start your Body Composition Stack research?
Each compound ships COA-verified, >98% purity, cold-packed for stability.
Frequently Asked Questions
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is a triple agonist that also targets the glucagon receptor, producing additive effects on energy expenditure beyond GLP-1 alone. Phase 2 data showed up to 24% body weight reduction for Retatrutide vs ~20% for Tirzepatide.
How do GH secretagogues like CJC-1295 and Ipamorelin work?
CJC-1295 is a GHRH analogue that stimulates pituitary GH release with an extended half-life due to DAC modification. Ipamorelin is a selective GHRP that triggers GH pulse without cortisol or prolactin elevation. Combined, they produce synergistic GH secretion through complementary receptor pathways.
Are GLP-1 peptide agonists available in oral format?
Orforglipron is a non-peptide GLP-1 receptor agonist with documented oral bioavailability — it is structurally resistant to peptidase degradation. Retatrutide and Tirzepatide are also available as capsules at Rainbow Peptide for oral administration research.
What does PT-141 research focus on?
PT-141 (Bremelanotide) is a melanocortin receptor agonist studied for its role in sexual function and arousal pathways. It acts centrally via MC3R and MC4R, differentiating it from vascular-acting compounds like PDE5 inhibitors.
For research use only. Not intended for human consumption. Must be 18+.